Pharmacological treatment for HT1 exists in the form of 2-(2-nitro-4-trifluoromethylbenzoyl)−1,3-cyclohexanedione (NTBC), a drug which inhibits the upstream enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD) thereby reducing the formation of toxic metabolites responsible for liver disease progression, thus essentially converting the disease into hereditary tyrosinemia type 3 (HT3), with a more benign phenotype4. This evidence concerns the gene HPD and liver disorder.